AstraZeneca: The Big China Bet

Manika PremsinghInvesting GroupFollow5ShareSavePlay(8min)CommentsSummaryAfter a big investment earmarked for the US last year, AstraZeneca now intends to invest $15 billion in China, reflecting its strategic focus.AZN has meant to expand in the market for some time, most recently in segments like cardio-metabolic and oncology. But its challenges in China are hard to overlook too.How the China story plays out still remains to be seen. In the meantime, while its 2026 outlook is positive, it's too bad that the stock is already fairly priced.Looking for more investing ideas like this one? Get them exclusively at Green Growth Giants. Learn More » jetcityimage/iStock Editorial via Getty Images If you thought the oncology giant AstraZeneca (AZN) would take a breather after announcing a $50 billion investment in the US last year, think again. Earlier this year, the company said it's committing This article was written byManika Premsingh4.48K FollowersFollowManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants, takes the theme a step further from LTT with a deeper dive into opportunities presented by the segment.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.